Morphic Medical

World’s first medical device designed to target the underlying cause of type 2 diabetes

Change Starts Within

Since Morphic Medical’s founding in 2003, our mission has been to alleviate the symptoms of type 2 diabetes and obesity for patients fighting these global epidemics worldwide. Our revolutionary RESET® therapy is a testament to Morphic Medical’s mission. The first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity. Morphic Medical’s aim is to bridge the gap between pharmaceuticals and surgery by providing an alternate treatment option to help reduce HbA1c and weight for individuals who are underserved by drugs and injections, but for whom surgery may not be an option.

Morphic Medical is headquartered in Boston, Massachusetts. Our team of business experts and industry veterans have a successful track record of pioneering and commercializing breakthrough healthcare technologies.


How RESET Works

Maintenance of Efficacy After RESET

BBC News Item

DJBL for the Treatment of Type 2 Diabetes and Obesity: EASD 2022

The Need By Numbers


2: IDF Diabetes Atlas 2021 – 10th Edition.

3: WHO and IDF 10th Edition (2021).

4: IDF 10th Edition (2021).

5: IDF 10th Edition (2021) and WHO.


Interested in joining the STEP-1 Trial?

Morphic Medical is currently enrolling patients for its STEP-1 clinical study of RESET® in the United States. Learn more if you or someone you know are interested in participating in the study and would like to see if you qualify to join.

RESET® is limited by Federal (US) Law to investigational use only and is not for sale in any geography.